News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn President Liz Magill awarded the 2023 President’s Innovation Prize toGabriella Daltoso, Sophie Ishiwari, Gabriela Cano, Caroline Amanda Magro, and Tifara Eliana Boyce for their project, Sonura.
Canberra IP will now link to Visible Legacy (VL) Navigator to Search, Navigate, and Connect with context to facilitate and speed up communication with a university licensing office and inventors.
In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy.
According to the latest Pitchbook-NVCA Venture Monitor report, the Greater Philadelphia area ranked fifth in the U.S. for the most closed venture capital deals in 2022 and the start of 2023.
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.
Penn was highlighted in The Daily Pennsylvanian for ranking first in annual licensing income among 153 research institutions.
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
The cohort started at the end of February and is underway. Teams are currently engaged in reaching out and conducting Customer discovery interviews.
It was a great opportunity to share the innovation initiatives coming out of Penn and Philadelphia with a global audience.
This in-depth interview with Swartley provides a comprehensive history about technology transfer at Penn as well as the establishment and current success of PCI.